ArticleJournal of clinical laboratory analysis2020
Potentiality of forkhead box Q1 as a biomarker for monitoring tumor features and predicting prognosis in non-small cell lung cancer.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Advances in the study of FOXQ1: biological functions and mechanisms.Frontiers in oncology · 2025Review
- LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1.Current cancer drug targets · 2024Article
- Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells.Cell stem cell · 2020Article
- Potentiality of forkhead box Q1 as a biomarker for monitoring tumor features and predicting prognosis in non-small cell lung cancer.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
- Retracted
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThis study aimed to explore the correlation of forkhead box Q1 (FOXQ1) with clinicopathological features and survival profiles in patients with non-small cell lung cancer (NSCLC).
methodsA total of 238 NSCLC patients with TNM stage I-III who underwent surgical resection were reviewed, and the expression of FOXQ1 in tumor and paired adjacent tissue was detected using immunohistochemistry assays. The clinical data and survival data of patients with NSCLC were retrieved and calculated.
resultsFOXQ1 expression was increased in tumor tissue (61.3% high expression and 38.7% low expression) compared with paired adjacent tissue (37.8% high expression and 62.2% low expression) (P < .001). In addition, high FOXQ1 expression was associated with larger tumor size (P = .042), lymph node metastasis (P = .040), and advanced TNM stage (P = .002). Disease-free survival (DFS) (P = .016) and overall survival (OS) (P = .008) were both reduced in patients with high FOXQ1 expression compared with patients with low FOXQ1 expression. Additionally, high FOXQ1 expression (P = .043), poor pathological differentiation (P = .003), and lymph node metastasis (P < .001) were independent risk factors for DFS, and high FOXQ1 expression (P = .021), tumor size (>5 cm) (P = .014), and lymph node metastasis (P < .001) were independent risk factors for OS.
conclusionHigh FOXQ1 expression is associated with advanced tumor features as well as undesirable survival profiles in patients with NSCLC, implying the potential prognostic value of FOXQ1 for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.